3Pauwels RA,Buist AS,Calverley PM,et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease.NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.Am J Respir Crit Care Med,2001,163(5):1256-1276.
5Jaffuel D,Demoly P,Gougat C,et al.Am J Respir Crit Care Med,2000,162(1):57-63.
6Calverley PMA,Pauwels RA,Vestbo J,et al.Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD.Am J Respir Crit Care Med,2002,165(8):A226.
7Vestbo J,Pauwels RA,Calverley PMA,et al.Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD.Am J Rspir Crit Care Med,2003,167(7):A89.
8Hanania NA,Darken P,Horstman D.The efficacy and safety of fluticasone propionate(250microg)/salmeterol(50microg) combined in the Diskus inhaler for the treatment of COPD.Chest,2003,124(3):834-843.
9Cazzola M,Di Lorenzo G,Di Perna F.Additive effects of salmeterol and fluticasone or theophylline in COPD.Chest,2000,118(6):1576-1581.
10Pauwels RA,Vestbo J,Calverley PMA,et al.Characterisation of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate combination in moderate to severe COPD.Am J Respir Crit Care Med,2003,167(7):A949.
8Celli BR. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. NEJM,2004,3(1) :1005-1012.
10ATS Committee on Proficiency Standards for ClinicalPulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respirtrit Care Med,2002, 166(1) :111-117.
